Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on December 13, 2004, primarily to disclose the approval of new forms of equity compensation agreements by its Compensation Committee. These agreements are for stock options and restricted stock awards granted under the company's 2000 Long-Term Incentive Plan. The filings detail the forms of agreements for various groups of employees, including named executive officers, other executive officers, and non-employee directors. For investors, this filing indicates updates to the company's executive and director compensation structure. The approval of these forms suggests that the company is either initiating new grant cycles or modifying existing programs for equity-based compensation. Investors should note that the specific terms, number of shares, and strike prices of any actual grants are not detailed in this 8-K, but the standardized forms establish the framework for future compensation decisions.
Key Highlights
- 1Regeneron's Compensation Committee approved new forms for stock option agreements and restricted stock award agreements.
- 2These agreements are governed by the company's 2000 Long-Term Incentive Plan.
- 3Specific forms of option agreements were approved for named executive officers and non-employee directors (Exhibit 10.01).
- 4Separate forms of option agreements were approved for other executive officers (Exhibit 10.02).
- 5A form of restricted stock award agreement was approved for executive officers (Exhibit 10.03).
- 6The filing relates to equity-based compensation for key personnel within the company.
- 7This 8-K serves as a disclosure of the standardized documents governing future equity grants.